Table 4. Univariate analysis for OS and... | American Society of Hematology

Table 4.

Univariate analysis for OS and PFS of the entire population of 155 patients

Variable	n	OS				PFS
Variable	n	Median, mo	IC 95%	% 5y	P	Median, mo	IC 95%	% 5y	P value
Age, y
≤50	102	120	42-198	55	.26	46	0-124	47	.115
>50	53	NR	-	65		NR	-	61
Stage
III-IV	128	120	42-192	54	.054	46	1-90	48	.057
Not III-IV	27	NR	-	77		NR	-	70
B symptoms	77	120	0-265	52	.095	36	0-114	47	.173
Not B symptoms	78	NR	-	64		NR	-	57
ECOG performance status not
≥2	94	NR	-	72	.0001	NR	-	63	.0001
≥2	61	13	4-23	38		8	3-13	34
Not increased LDH	55	NR	-	81	.002	NR	-	70	.002
Increased LDH	100	31	-	46		15	0-40	42
IPI
Not int. high-high	83	NR	-	69	.012	NR	-	59	.027
Int. high-high	72	31	0-84	47		13	0-47	43
CD4 <200/uL	70	73	0-155	51	.13	46	0-102	47	.357
Not CD4 <200/uL	85	NR	-	64		NR	-	56
Ki67 ≥90%	63	NR	-	65	.058	NR	-	64	.007
Not Ki67 ≥90%	92	117	35-200	53		16	0-42	43
MYC+	43	120	12-228	58	.942	50	0-143	49	.712
MYC–	112	NR	-	59		NR	-	53
BCL2 rearranged	9	18	0-45	44	.37	9	5-13	0	.016
Not BCL2 rearranged	146	120	-	59		NR	-	55
BCL6 rearranged	32	120	0-270	52	.226	10	0-58	39	.089
Not BCL6 rearranged	123	NR	-	60		NR	-	56
DHL or THL
Yes	10	18	0-76	50	.217	9	3-15	30	.048
No	145	NR	-	59		NR	-	53
iCT
Yes	42	NR	-	59	.297	NR	-	57	.181
No	113	120	62-178	58		59	0-135	50

Variable	n	OS				PFS
Variable	n	Median, mo	IC 95%	% 5y	P	Median, mo	IC 95%	% 5y	P value
Age, y
≤50	102	120	42-198	55	.26	46	0-124	47	.115
>50	53	NR	-	65		NR	-	61
Stage
III-IV	128	120	42-192	54	.054	46	1-90	48	.057
Not III-IV	27	NR	-	77		NR	-	70
B symptoms	77	120	0-265	52	.095	36	0-114	47	.173
Not B symptoms	78	NR	-	64		NR	-	57
ECOG performance status not
≥2	94	NR	-	72	.0001	NR	-	63	.0001
≥2	61	13	4-23	38		8	3-13	34
Not increased LDH	55	NR	-	81	.002	NR	-	70	.002
Increased LDH	100	31	-	46		15	0-40	42
IPI
Not int. high-high	83	NR	-	69	.012	NR	-	59	.027
Int. high-high	72	31	0-84	47		13	0-47	43
CD4 <200/uL	70	73	0-155	51	.13	46	0-102	47	.357
Not CD4 <200/uL	85	NR	-	64		NR	-	56
Ki67 ≥90%	63	NR	-	65	.058	NR	-	64	.007
Not Ki67 ≥90%	92	117	35-200	53		16	0-42	43
MYC+	43	120	12-228	58	.942	50	0-143	49	.712
MYC–	112	NR	-	59		NR	-	53
BCL2 rearranged	9	18	0-45	44	.37	9	5-13	0	.016
Not BCL2 rearranged	146	120	-	59		NR	-	55
BCL6 rearranged	32	120	0-270	52	.226	10	0-58	39	.089
Not BCL6 rearranged	123	NR	-	60		NR	-	56
DHL or THL
Yes	10	18	0-76	50	.217	9	3-15	30	.048
No	145	NR	-	59		NR	-	53
iCT
Yes	42	NR	-	59	.297	NR	-	57	.181
No	113	120	62-178	58		59	0-135	50

Only those parameters that achieved statistical or borderline significance on at least 1 end point or parameters with clinical relevance are listed.

DHL or THL, double-hit or triple-hit lymphoma; NR, not reached.